News

A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia’s drug candidate EVX-101, which is in development for major depressive disorder (MDD).

BioPharm International interviews our VP of Scientific Consulting, John McDermott, who discusses the latest trends in drug development outsourcing.

Chris Roe, Principal Research Fellow, and Ricardo Diaz de Leon Ortega, Modelling and Simulation Research Fellow, attended and presented at the Basic Biopharmaceutics Workshop hosted by The Biopharmaceutics Focus Group of the Academy of Pharmaceutical Sciences UK in London.

Nick McEntee, Executive Director, Head of UK GMP Operations discusses strategies for flexible, on-demand manufacture of clinical trial materials with Contract Pharma.

Oxilio Limited (“Oxilio”) reports favourable safety and pharmacokinetic data from a single-part, five-period, sequential, open-labelled Phase 1 study of OXL001 in healthy male volunteers that is being conducted at Quotient Sciences.

Quotient Sciences' Nand Singh featured in BJCP's article on 'Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modeling'.